

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 July 2024 (18.07.2024)



(10) International Publication Number
WO 2024/149345 A1

(51) International Patent Classification:

A61K 47/65 (2017.01) *A61K 47/61* (2017.01)
A61K 47/60 (2017.01) *C07H 5/06* (2006.01)
A61K 47/54 (2017.01) *A61P 35/00* (2006.01)
A61K 47/56 (2017.01)

(21) International Application Number:

PCT/CN2024/071901

(22) International Filing Date:

11 January 2024 (11.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/071778

11 January 2023 (11.01.2023) CN

(71) Applicant: **PROFOUND BIO US CO.** [US/US]; 14241 NE Woodinville-Duvall Rd. #228, Woodinville, Washington 98072 (US).

(72) Inventors: **LIU, Haidong**; Suite 101 & 102, Bldg 1, P3A 1 Xinze Street, SIP, Suzhou, Jiangsu 215123 (CN). **WANG, Guobao**; Suite 101 & 102, Bldg 1, P3A 1 Xinze Street, SIP, Suzhou, Jiangsu 215123 (CN). **JIANG, Xiaolong**; Suite 101 & 102, Bldg 1, P3A 1 Xinze Street, SIP, Suzhou, Jiangsu 215123 (CN). **SHANG, Xiao**; 14241 NE Woodinville-Duvall Rd. #228, Woodinville, Washington 98072 (US).

(74) Agent: **METIS IP (CHENGDU) LLC**; Room 401, 4th Floor, Unit 1 of Building 1, No. 269 North Section of Hupan Road, Tianfu New District, China Free Trade Zone (Sichuan), Chengdu, Sichuan 610213 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

(54) Title: LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME





FIG. 1



(57) Abstract: It provides linker compounds, or stereoisomers or salts thereof, including (a) a linker unit having from 1 to 4 attachment sites for a drug unit and having one of the following structures (i) or (ii): (b) at least one polar group containing a polymer unit, optionally a sugar unit, optionally a carboxyl unit, and combinations thereof; and (c) optionally a stretcher group having an attachment site for a targeting group, wherein a-is an attachment site to an enzyme-cleavable group; 3-is an attachment site to the at least one polar group; 6-is H, an attachment site to at least one of the drug unit, or an attachment site to a linking group attached to the at least one of the drug unit. It also provides drug-linker compounds and conjugates formed from linker compounds, as well as related pharmaceutical compositions and methods.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))